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ABSTRACT

The Bi-directional Relationship Between Gut Microbiota and Autoimmunity

by

Trevor O. Kirby

Spring 2018

Humans serve as a major reservoir for a vast number of microbiota. These microbes have
evolved symbiotic relationships with humans due to their close proximity with their host.
As a result, the immune system adapts to the microbiota thus modulating immunological
function. Autoimmunity is a state in which there are aberrant immune responses
produced against host tissue. Intestinal bacteria are directly impacted by instances of
inflammation brought on by autoimmunity. The complicated nature between
autoimmunity and bacterial modulation demonstrates a bi-directional relationship. Here,
we utilize experimental autoimmune encephalomyelitis, a model for multiple sclerosis, to
explore the bi-directional relationship that disease and microbiota share. We demonstrate
that disease severity, as well as time point post disease induction, shapes the structure and
function of the gut microbiome. Additionally, antibiotic intervention modulates the
symptoms of disease by upregulating the expression of T regulatory cells. Further, we
show that a genetically engineered Lactococcus lactis expressing the colonization factor
antigen I from Escherichia coli acting as an immunomodulatory probiotic reduced the
severity of disease.
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Chapter 1: The gut microbiome, multiple sclerosis, their relationship, and therapeutic
approaches
Overview
Bacteria are prokaryotic microorganisms with a vast array of functions and
characteristics. Diverse bacterial metabolism allows them to occupy almost every niche
possible on Earth. Their range spans everywhere from extreme conditions such as deep
sea hydrothermal vents to more mild conditions such as on plants growing in temperate
climates. As a consequence, every facet of human biology is exposed to bacteria.
Whether it be from dust in the air to the food consumed, humans are constantly exposed
to bacteria.
Generally, there is a misconception that bacteria are harmful to humans and pose
a threat to human health. There are more bacteria that establish symbiotic relationships
with us, commensal or mutualistic, than bacteria that are pathogenic. The symbiotic
bacteria participate in with their human host are analogous to symbioses present in
traditional ecological settings. Commensal bacteria will reside in or on the human host
and receive nutrients from their host’s diet and or metabolites produced from other
bacteria. These bacteria do not help their host but they also do not cause disease for their
human host. Mutualistic bacteria will behave much like commensal bacteria but their
presence will provide a direct benefit to their host. As science continues to investigate
the bacteria associated with humans, their apparent function and benefits become more
apparent.

The Gut Microbiome
Bacteria must compete and interact with other microbes such as other bacteria,
viruses, fungi, archaea, and single celled eukaryotes as well as interact with the
environment around them. These interactions form intricate microbiomes; a microbiome
is best defined as the summation of all these microbes as well as the combination of all
the genetic material from them in a defined space and time. The sum of all microbes
within a given niche is defined as microbiota. Several types of microbiomes exist and are
generally defined by the physical space in which they are located. Although scientists
study all types of microbiomes, particular interest has been focused on human associated
microbiomes due to their relevance to human health. Because of this, and in association
with its highly complex structure and broad array of effects, the best studied microbiome
is the human gut microbiome (and by proxy the murine gut microbiome).
The best studied microbiome is the human gut microbiome (and by proxy the
murine gut microbiome) that spans the entire digestive tract including the stomach, small
intestine, caecum, large intestine, and rectum. Across the geographic location, the gut
environment varies dramatically in both its physical and chemical nature. The physical
and chemical variation dictate the structure of the microbiota present. For example, the
approximate pH of the duodenum is 6 whereas the pH of the terminal ileum ranges from
6-7.4.1 Mucus levels tend to differ between the large and small intestines as well which
directly regulates the bacterial communities present.2 Although the physical properties of
the gastrointestinal tract shape bacterial populations, microbes persist and thrive.
Therefore, the gastrointestinal tract physiology evolved to interact and respond to the
microbiota present.
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Bacterial metabolism also plays a role in which taxa are present at differing
geographic locations. For instance, fatty acids and simple carbohydrates derived from
food are absorbed in the small intestines and therefore bacteria that can ferment complex
carbohydrates are the ones that can survive.3 As a consequence, the Bacteroides are the
most studied taxa that can perform this metabolic task.4 Additionally, human diet plays a
critical role at shaping the gut microbiome. Studies in which humans switch their diets
from being primarily plant based versus primarily animal based experience a profound
effect on the composition of the gut microbiota.5 The effect of diet on the composition of
the gut microbiome generally is centered on the fact that it dictates what nutrients are
available for the microbiota. Therefore, nutrient availability as well as retention is
critical.
Antimicrobials play an additional role at shaping the structure of the gut
microbiome. Specialized epithelial immune cells known as Paneth cells secrete
antimicrobial compounds that alters the growth of bacteria near the mucosal surface.6
These compounds are cationic peptides that interacted with charged membranes of
bacteria. Some bacteria, however, have evolved to respond to these charged peptides;
some gram negative bacteria have modifications in the lipid A component of the outer
membrane which renders them resistant to these peptides.7 Interestingly, however, the
concentration of antimicrobials are higher towards the proximal end of the small intestine
which results in higher abundance and diversity in the distal ends.3
Secreted Immunoglobulin A (sIgA) and other immune system mediated responses
dictates what bacteria persist where. Intestinal mucosa contains large quantities of sIgA
to monitor the gut microbiota.3 The non-pathogenic bacteria becomes coated in sIgA to
3

maintain tolerance from the host. Coats of sIgA on bacteria reduces inflammatory
signaling and reduces changes to bacterial gene expression.8 This process allows
homeostasis between the host and the microbiota to be maintained. However, this
process can be sometimes utilized by pathogenic bacteria as well. In the case of some
species of Helicobacter, these pathogens are coated in sIgA as well resulting in an
inappropriate tolerance response by the host.9 Therefore the complexity of homeostasis
between non-pathogenic bacteria and the host is more complicated than simply just sIgA
coating. Some believe that the bacteria themselves have to promote their own tolerance
to the host for their own survival. This is shown the case of Bacteroides fragilis. The
polysaccharide A component of the bacterial capsule on B. fragilis has been shown to
exert anti-inflammatory properties by stimulating the secretion of IL-10 by regulatory T
(Tregs) cells.10 This process is seen in other bacteria as well suggesting that the need for
self-promoting tolerance is necessary.
The Anatomy of the Gut Epithelium
The gastrointestinal tract is the site of interaction between the body’s largest
concentration of immune cells and the gut microbiota.11 The gut epithelium acts as a
major barrier between the external environment and the host’s internal environment. The
human digestive tract essentially is a long tube; starting from the mouth and extending
down the esophagus, past the stomach and through the small intestines and large
intestine, finally ending past the colon at the anus; everything humans eat needs to be
separated from the inside of the body.
Goblet cells in the intestinal epithelium produces mucus to form a matrix between
the external environment and the intestinal epithelial surface.12 Besides the mucus layer,
4

only a single layer of epithelia separates the intestinal lumen contents from the
underlying connective tissue and interior milieu.13 Due to this, the intestinal epithelium
developed specialized cells types to deal with the exposure. As previously discussed,
Paneth cells play a critical role in maintaining the security of the gut epithelium by
secreting antimicrobial peptides. Additionally, cells expressing CD24 resides in the
colonic crypts which elicit similar responses to the Paneth cells.14
The thin layer of epithelium generates a barrier that can prevent material from the
intestinal lumen from entering the interstitial space of the body. Tight junction protein
complexes regulate the paracellular permeability of the intestinal epithelium.13 The
permeability of the epithelium varies across the intestines geography and is largely
determined by the amount of tight junction protein complex expression. The protein
complex consists of transmembrane proteins such as occludin, claudin, junctional
adhesion molecules, tricellulin, and intracellular scaffold proteins like zonula
occludens.13 The pathogenesis of several diseases such as inflammatory bowel disease,
celiac disease, and even food allergies have been attributed to the hyperpermeability of
the intestinal barrier.15 Interestingly, alterations in normal gut microbiota has been noted
to cause changes in intestinal permeability.16 In the case of Gulf War Illness, chemical
injury results in the alteration in intestinal microbiota resulted in a down regulation of
occludin expression and an increase in intestinal permeability. The leachates then cause
endotoxemia leading to the upregulation of toll like receptor-4 activation in the intestine
as well as the brain.16
Because of the high intake of microbes via digestion and the critical role intestinal
epithelia plays, the immune system and intestinal physiology evolved to monitor the
5

traffic. The lymphatic system is a network of vasculature that allows leukocytes to travel
the body and monitor antigens. For the gut, there is a specialized set of lymphatic tissue
known as the gut associated lymphoid tissue (GALT). The GALT is comprised of the
Peyer’s patches, mesenteric lymph nodes, lymphatic vasculature, as well as other
lymphoid aggregates. These structures work in tandem to protect the gut from
pathogenic microbes while monitoring the commensal or mutualistic bacteria.
The Gut/Immune System Nexus
As bacteria and their metabolites persist in the gut, the GALT-associated immune
cells must monitor every aspect of the intestinal lumen to catch and eliminate pathogens.
M cells, a specialized epithelial cell of mucosa-associated lymphoid tissue, transports
antigens from the intestinal lumen to immune cell populations. M cells allow dendritic
cells to sample antigens from the lumen and endogenously prepare the antigen for
presentation to T effector cells via the major histocompatibility complex (MHC) class II
molecule. This process then, in turn, can activate the T cells and differentiate them into
specialized effectors to perform functions necessary for dealing with the microbe
expressing the activating antigen. Whether it is to mount an immunological response or
to disregard the antigen, the interaction between the host immune system and the microbe
will occur. This process is mediated by the subsets of T cells as well as anergy.
In the case of pathogenic antigens, the need to activate pro-inflammatory T cells
may be necessary. T helper (Th) cells such as Th1, Th2, and Th17 can help mobilize and
recruit innate immune cells to the site of the pathogen. This process is mediated by the
secretion of cytokines and chemokines. Cytokines are molecules such as interferons,
interleukins, growth factors, and other compounds that have some effect on other immune
6

cells. CD4 T cells express surface receptors known as T cell receptors that can identify
antigens presented by MHC molecules. Upon this union, the naïve T cell will
differentiate into one of the various T helper cell subsets depending on the additional
signaling molecules the naïve T cell encounters during co-stimulation. As an example,
Th1 cells can be activated after co-stimulation and go on to secrete interferon-gamma
(IFN-γ) to activate other Th1 cells in the immediate area.17 The non-cognate stimulation
of Th1 cells allows the immune system to clear pathogenic intracellular bacteria. These
cytokines and chemokines recruit innate immune cells such as neutrophils to the site of
the infection; the immune system then can eliminate the threat of the pathogen via
phagocytosis, neutralizing antibodies, or antibody mediated engulfment.
In the case of non-pathogenic antigens, there is a need to activate antiinflammatory T cells to prevent immune cell mediated clearance of the pathogen. As
previously stated, not all of bacteria are pathogenic but rather commensal or mutualistic.
Therefore it is critical for the immune system to have a way to virtually ignore the
antigens of these non-harmful bacteria. Previously discussed, B. fragilis had the ability to
stimulate its own immunotolerance by stimulating the production of Tregs which would
secrete IL-10.10
Additionally, anergy could also be used to prevent an immunological response
against non-pathogenic bacteria. Anergy is defined as being the absence of a normal
immunological response to an antigen; achieving anergy against non-pathogens could be
another way to ignore non-pathogenic antigens. Toll like receptor-7 can be engaged
resulting in an intracellular calcium flux with the activation of a NFATc2-dependent
anergic gene expression program that ultimately results in T cell non-responsiveness.18
7

The processes that maintain the balance between pro- and anti-inflammatory
processes are complicated and in some cases depend on the bacteria or viruses
present.10,18 Additionally, the gut microbiome is shaped by various factors including host
genetics, geographical location, diet, lifestyle choices, prescribed pharmaceuticals, mode
of delivery during birth, antibiotic exposure, and possibly even disease states themselves.
When these factors tip the gut microbiome out of balance, there can be an induced
imbalance between these pro- and anti-inflammatory responses that can result in disease.
This proposed disease model is known as dysbiosis: gut microbial imbalances that result
in, or are a result of, disease states. Generally, labs are investigating whether these
alterations in gut microbiota result in disease. However, it is possible that alterations in
the balance between pro- and anti-inflammation can alter the structure and function of the
gut microbiota as a function of diseased states.
Multiple Sclerosis and Autoimmunity
Autoimmunity is best described as being a process in which the host’s immune
system fails to distinguish self from non-self and begins to elicit immunological
responses against host tissue. Mechanisms that drive autoimmunity remain to be
elucidated; however, it generally is understood that exacerbated pro-inflammatory
responses can exacerbate the tissue damage that characterizes the process of
autoimmunity. Therefore, understanding the extent of inflammation induced by dysbiosis
becomes critical to investigate. The importance of gut microbiota in context to immune
function can be seen when comparing traditional mice to gnotobiotc mice. Gnotobiotic
mice exhibit reduced immune function with physiological abnormalities such as
increased intestinal permeability. Dysbiosis can be induced by the same environmental
8

factors that have been described to potentially illicit autoimmunity. Moreover, dysbiosis
has been noted in several experimental models of autoimmunity as well as patients
suffering from autoimmunity.19-22 These phenomena can provide evidence that intestinal
dysbiosis is critical in the development of autoimmune disorders.
Our lab primarily focuses on Multiple Sclerosis (MS), a clinically common
autoimmune disease. MS affects millions of individuals worldwide; many of these
individuals reside in northern geographic locations such as the Pacific Northwest. For
these individuals the quality of life slowly diminishes as the disease progresses, as the
host immune system attacks the insulating structure known as the myelin sheath that
surrounds the axon shaft of neurons in the spinal cord.23 When the sheath is degraded,
the ability for electrical signals to be sent through the axon is reduced thus resulting in
paralysis and other symptoms. The most prevalent form of MS is relapsing-remitting MS
(RRMS) that affects 85% of the total patient population; RRMS is initially diagnosed as a
syndrome of neuronal dysfunction with a repeating series of relapses and remissions that
follow over time.24 Approximately 70% of RRMS patients develop secondaryprogressive MS (SPMS), which causes a steady and progressive neurological
impairment.24,25 The precise reason as to why immune cells destroy myelin remains
unclear.24,25 In MS, the myelin sheath that surrounds the axons of neuronal cells is
degraded by host immune cell populations. Although the exact etiology is debated, there
are hallmark events that undeniably occur.
Generally, MS arises in genetically susceptible individuals. Genetic variation is
attributed to about one third of the disease risk.26 Environmental conditions as well as
lifestyle choices play an additional factor in disease risk. Lacking a predominant
9

exogenous risk factor, there is ambiguity as to whether MS starts in the periphery or in
the central nervous system (CNS).27 In peripheral models of MS, pathogenic T cells are
activated and subsequently released to the draining lymph nodes.27 From the draining
lymph nodes, these pathogenic T cells can enter circulation and gain access to the central
nervous system by trafficking with activated B cells and monocytes.27 Intrinsic models
propose that the rise of autoreactive lymphocytes is secondary to intrinsic CNS damage.27
Additionally, autoreactive B cells can be found in the meninges, parenchyma, and
cerebrospinal fluid.27 These autoreactive B cells can secrete antibodies which tend to
increase with age in MS patients.28 There is a lack of known autoantigens which makes
the mechanisms behind autoreactive B cell pathology speculative;27 however, nextgeneration sequencing has provided evidence that antigen-experienced B cells potentially
go through maturation prior to entering the CNS.29 Inflammation is a primary result from
autoreactive lymphocytes. These responses cause axonal damage and could potentially
trigger a self-sustaining chronic neurodegenerative process.27 As a result, resident CNS
cells such as the microglia and astrocytes additionally secrete inflammatory molecules
further exacerbating the neurodegeneration.30 The extent to which all these cell
populations work in tandem to cause disease highlights the need to prevent the initial
onset of inflammation and neurodegeneration.
Compounding the magnitude of autoreactive immune cell populations, defective
Treg cells have also been noted in MS.31 Defective Tregs could contribute to the
production of autoreactive lymphocytes and additionally exacerbate the effects of
preexisting autoreactive lymphocytes. Studies show that Tregs are lower in numbers and
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have reduced functionality in patients with MS.32 Ultimately, it is the occurrence of
defective Treg cells that can help explain why autoreactive immune cells arise.
The degradation of the myelin sheath by host immune cells is generally mediated
by the T helper 17 (Th17) cells.33 The imbalance between effector T cell and Tregs leads
to pro-inflammatory states which characterizes MS. The increased levels of Th17 cells
secrete pro-inflammatory cytokines and chemokines that recruit immune cells for the
degradation events. Reduced and dysfunctional Tregs will fail to keep the exacerbated
Th17 in check resulting in myelin degradation.
Gut microbial imbalances tend to shift towards a pro-inflammatory state that
have profound effects on the intestinal physiology of the individual. Additionally,
dysbiosis has been associated with intestinal barrier disruptions. When the integrity of
these tight junction protein complexes diminishes there is an increase in intestinal
permeability; the bacterial antigens can pass out of the intestinal lumen and travel to other
locations in the body. As a result, levels of antigens, like the endotoxin
lipopolysaccharide, can increase in the blood circulation which could have systemic
inflammatory effects.34 Systemic translocation of bacterial antigens can have a profound
effect on CNS immunity and impact the integrity of the blood-brain barrier.35 This
process can result in the ultimate passage of autoreactive lymphocytes into the CNS and
have direct access to the myelin sheath.
The Bi-directionality of the Gut Microbiome
As previously discussed, autoimmunity has been shown to be impacted by the gut
microbiome. However, it has also been theorized that disease itself can shape the
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structure and function of the gut microbiome. What this implies is that there is a bidirectional relationship between diseased states and the structure and function of the gut
microbiome. This then raises more questions; what comes first: the disease or the
aberrant gut microbiome?
In instances of some autoimmunity, the aberrant gut microbiome precedes the
onset of disease. This phenomenon can be seen directly with Type 1 Diabetes (T1D).
Intestinal dysbiosis has been noted in both humans and animal models of T1D. In a study
conducted by Costa et al., the murine model for T1D was protected against the
development of insulitis when treated with antibiotics.36 The model utilized in this study
was a streptozotocin-induced T1D models in which the onset of insulitis is brought on
upon by the bacterial translocation event. The utilization of antibiotics prevented
bacterial translocation and thus prevented the onset of disease. Moreover in humans,
bacterial translocation has been theorized as being a major factor that leads to insulitis.
Bacterial translocation through the duodenum as a result of intestinal dysbiosis can cause
the bacterial antigens in the pancreatic ducts to recruit immune cell populations resulting
in the destruction of β-cells.
On the other hand, there is an increasing interest in determining how disease itself
shapes the gut microbiome. Risk factors that have been associated with autoimmunity
also impact the gut microbiome.37 Additionally, autoimmunity can directly impact how
the immune system responds to the gut microbiota. In the case of inflammatory bowel
diseases, the immune system targets resident microbiota thus altering the overall structure
of the gut microbiome.38 Targeting non-pathobionts and clearing them from the
intestines could have profound impacts on the immune system of the host. If a
12

populations of bacteria that promotes anti-inflammatory responses are eliminated it is
possible that unchecked systemic inflammation could occur thus further exacerbating the
initial autoimmune disease.
In the case of MS, dysbiosis is present.39-41 Therefore, there is ample data to
support the hypothesis that the gut microbiome can play a role in the development of MS.
However, very little is known about how MS affects the composition of the gut
microbiome. Understanding how MS pathology affects gut microbiota can give insight
to novel therapeutic approaches to impact disease progression. Similarly, dysbiosis
drives disease progression in the inflammatory bowel disease model, therefore it is
possible that dysbiosis also promotes inflammation in the MS model. It is hypothesized
that there is a bi-directional relationship between the gut microbiota and MS. The
structure and function of the gut microbiome shapes MS pathology at the same time MS
disease progression also shapes the structure and function of the gut microbiome.
The structure of the dysbiotic MS gut is so influential to disease progression that
fecal transplantation of the gut microbiome can influence the progression of experimental
autoimmune encephalomyelitis (EAE), a model for MS in mice. When fecal material
from discordant monozygotic twins was transplanted into mice, there was a profound
impact on spontaneous EAE disease incidence.42 The MS gut microbiome had the ability
to increase the likelihood of spontaneous EAE induction in mice as opposed to the
healthy twin. Moreover, the stool from MS patients also increased the severity of EAE in
mice.43 Therefore, it is clear that targeting the gut microbiome might have profound
impacts on MS pathology.
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Targeting the Gut Microbiome with Therapeutic Options
As summarized earlier, recent experimental evidence and clinical data suggest
that the gut microbiome might be a major factor regulating autoimmunity. Targeting the
gut microbiome with therapeutics could have profound effects in disease progression as
well as managing symptoms of disease. The extent and approach towards modulating the
gut microbiome can follow many directions; it is crucial to balance the positive and
negative impacts of each therapeutic option. Gut microbiome-based therapeutic
approaches could have beneficial effects in terms of disease management but also have
unintended adverse side effects. Furthermore, some therapeutic options can work for
some autoimmune diseases but not others. Therefore, again, assessing proposed
therapeutics are crucial and developing therapeutics with less negative consequences is
essential.
Antibiotic Therapy
Utilizing antibiotics to therapeutically target the gut microbiome has been
proposed for models of Type 1 Diabetes as well as Fulminant Ulcerative Colitis.44,45
Additionally, a study conducted by Nakamura et al. set out to test the efficacy of an
antibiotic cocktail on an experimental autoimmune uveitis (EAU) model. Autoimmune
uveitis has both a genetic and environmental culmination that impacts disease
susceptibility, and is characterized by a distinct increase in Th17 cell populations with a
decrease in Tregs cell populations.46 Utilizing an antibiotic cocktail consisting of
ampicillin, vancomycin, neomycin, and metronidazole, the researchers noted that clinical
scores of EAU were significantly reduced compared to the control group when the
antibiotics were administered orally. The bacterial phyla Firmicutes and Bacteroidetes as
14

well as the class of Alphaproteobacteria were reduced while there was an increase in the
class of Gammaproteobacteria. More importantly, the utilization of antibiotics
significantly increased the expression of CD4+Foxp3+ Treg cell populations with a
reduction in IL-17 producing Th17 cells.46 Although the reduction in Th17 cells was not
significantly reduced, it was still reduced substantially. Taking this all into consideration,
the treatment of broad spectrum antibiotics conferred protection against the EAU
pathology.
Experimental Autoimmune Encephalomyelitis (EAE), a model disease for MS,
has also been explored in the context of antibiotic intervention. A study by OchoaRepáraz et al. demonstrated that broad-spectrum antibiotic interventions affected the
balance between inflammation and inflammatory regulation in EAE by modulating
intestinal microbiota and, as a consequence, Treg cell populations.47 Additionally,
Yokote et al. reported similar findings but noted that the alterations in intestinal
microbiota impacted the Natural Killer T cell populations.48 These experiments analyzed
the impacts antibiotic intervention could have on modulating EAE in SJL as well as C57
mice. In the case of germ-free mice, mice with no microbiota, it was noted that
colonization with segmented filamentous bacteria induced intestinal Th17 cell
production.49 Additionally, the colonization of segmented filamentous bacteria was
correlated with the increased expression of inflammatory genes.49 In the case of EAE,
when germ-free mice were monocolonized with segmented filamentous bacteria they
experienced exacerbated symptoms of EAE which generally are not present in the germfree model of EAE.50
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CNS diseases also have studied in terms of how antibiotics impact disease
pathology. Parkinson’s disease (PD) patients report gastrointestinal distress as well as
exhibit intestinal inflammation well before symptoms of motor deficits.51-53 A study
conducted by Sampson et al. hypothesized that alterations in the gut microbiota by
antibiotic interventions could alleviate PD pathology due to the association of intestinal
complications and the tight interactions between the gut and the CNS.54 The treatment of
broad-spectrum antibiotics did, in fact, confer protection against motor dysfunction in a
murine model. These findings support the notion that therapeutic targeting of the gut
microbiome with antibiotics may be efficacious.
In the cases above, antibiotic interventions have conferred protection in these
models of disease by altering the gut microbiome. However, the usage of broad spectrum
antibiotics can also have adverse effects by the same mechanism. Clostridium difficile,
an opportunistic pathogen, can infect the host after antibiotic treatments with symptoms
ranging from diarrhea to pseudomembranous colitis and can be in some cases life
threatening.55 The exposure to antibiotics cause structural changes in the gut microbiome
leaving the host susceptible to opportunistic infection from C. difficile as well as other
enteric pathogens.56 Children exposed to antibiotics within the first three years of life
exhibit lower diversity in their gut microbiome. Moreover, these microbiome structures
are less stable in exposed children than in non-exposed children.57
Phage Therapy
In response to the negative impacts of broad spectrum antibiotic usage the notion
of using bacteriophage (phage) as a therapeutic has been discussed. Phage are bacteriaspecific viruses that can be altered to target bacterial populations of interest while leaving
16

others untouched. The oral delivery of phage has been considered to be safe and have the
capability to bypass intestinal epithelia and penetrate the GALT as well as the blood
stream.58,59 This ability to penetrate the GALT as well as the blood stream makes phage
therapy extremely attractive to deal with bacterial translocation that can lead to diseased
states such as those seen in T1D.
Phage play a critical role in shaping the gut microbiome naturally and constitutes
the bulk of the intestinal viriome.60,61 However, phage can also be pathogenic by
contributing to intestinal dysbiosis; their uncontrolled destruction of beneficial bacteria
can have consequences to the overall structure and function of the gut microbiome.62
Additionally, phage also can have the unintended impact of horizontally transferring
antibiotic resistance to their bacterial hosts.63 Lysogenic phage have had antibiotic
resistance genes associated within their genomes.64 To some, this has rendered the notion
of phage therapy obsolete. However, researchers have been designing “smart” phage
cocktails that bypass horizontal gene and appear promising.65 Ultimately, there is still a
lot of unanswered questions and concerns in regards to the safety and efficacy of phage
therapies in terms of unintentional microbiome impacts.
Fecal Transplantation
The approach of antibiotic interventions and phage therapeutics is to target
bacterial populations and remove or reduce them from the gut microbiome. Fecal
transplantations act as whole gut microbiome replacements in hopes of correcting
aberrant gut microbiome structures and functions. The efficacy of fecal transplantations
is also quite high; thus, fecal transplantations is a common therapeutic to treat patients
with C. difficile.66,67 Conceptually, by eliminating the host’s aberrant gut microbiome
17

and replacing it with a healthy gut microbiome, the diseased state will be rectified. This
largely is the case in patients suffering from C. difficile infections and has revealed
infection clearance with a single treatment.66,67 The efficacy of fecal transplantations has
promise in other diseases, including autoimmunity and neurological disorders, as well.
In the instance of autoimmunity, again, fecal transplantations has been proposed
as a therapeutic strategy to treat irritable bowel syndrome as well as inflammatory bowel
disease.68 In inflammatory bowel disease, there is instances of dysbiosis with an increase
in pro-inflammatory bacterial species.69 A meta-analysis from Colman et al. showed that
fecal transplantation therapy put 45% of patients into clinical remission and reduced the
need for other forms of anti-inflammatory therapeutics.70 Symptom rescue was attributed
to microbiota manipulation; the gut microbiome changes in the patients in response to
fecal transplant therapy.71
Satisfactory results from fecal transplantation are apparent, however there are still
concerns regarding safety. For example, some of these concerns regard the route of
administration, frequency of applications, screening the microbiota from the donor, the
preparation protocol of the stool sample from the donor, what antibiotics should be
administered and their frequency prior to fecal transplantation, among others.69 Some of
these concerns are very valid and have been partially explored. For example, in the study
by Friedman-Korn et al., instances of aspiration occurred in two patients when the fecal
transplantation was administered via gastroscopy.67 It was proposed that that
colonoscopy would be a safer route for the therapy. This claim was then assessed later in
the study by Bamba et al.66 Still, several concerns remain. The impact donor stool can
have an immense effect on an individual. Data supports the notion that fecal
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transplantations can play a role in the development of obesity.72 Ultimately, the risks and
rewards of fecal transplantation therapy still needs extensive exploration.
Dietary Supplementation
Diet, itself, plays a major role in shaping the structure of the gut microbiome. By
manipulating compounds and nutrients the gut is exposed to, it is possible to alter the
structure and function of the gut microbiome. Western diets generally consist of high
amounts of saturated fats and carbohydrates which can lead to chronic inflammatory
states.73 Recognizing the impacts of the Western diet and identifying routes to
supplement the diet to reduce the negative impacts and chronic inflammatory states could
be a therapeutic avenue to assess.
Naturally occurring compounds have been noted to have profound impacts on
metabolic health. Chlorogenic acid is a phenolic acid commonly found in beverages
commonly ingested by humans worldwide, such as coffee and tea.74 It has been shown to
inhibit glucose-6-phosphate translocase as well as hepatic glucose-6-phosphatase.75
These properties would limit the amount of carbohydrate absorption by the small
intestine as well as the extent in which glucose is released.75 Chlorogenic acid has also
been noted to have antimicrobial activities against some bacterial species that constitute
parts of the gut microbiome.76 Glycyrrhizin, a compound found in the roots of the
Glycyrrhiza glabra plant, has also been identified for its anti-inflammatory properties.77
When glycyrrhizin was administered into high-fat induced obese rats, the glycyrrhizin
caused the rat to have reduced insulin resistance, lose weight from the diet, and reduced
obesity-induced oxidative stress.78 The impact glycyrrhizin has on bacteria has not been
noted nor has it been explored in context to the gut microbiome. The overall impacts
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these plant based compounds have on the gut microbiome is vastly unknown and
warrants further investigation.
Utilizing dietary supplements as a therapeutic avenue for MS is still largely
unexplored. The usage of probiotics however, has been gaining attention. A probiotic is
generally described as bacteria that is administered orally to have some beneficial impact
on the health of the individual. Moreover, probiotics are a non-toxic immunomodulatory
agent that can orally be used in conjunction with current therapeutics for MS.79 Studies
have shown that oral administration of probiotics have positive immunomodulatory
effects that could work in tandem with current pharmaceutical therapeutics. Probiotics
will further be discussed later.
Limitations of Current Therapeutics
Ultimately, all these therapeutic options have not been explored fully been for
MS. Moreover, the therapeutics available for MS are quite limited. There is no cure for
MS and most of the therapeutics available only treat symptoms of the disease. Current
pharmaceuticals exist that act as immunosuppressive or immunomodulatory agents;
however, many of them have limited efficacy and have in some cases severe side
effects.80 Moreover, there is yet no commercial therapeutic for secondary progressive
MS. Because of the current limits of the pharmaceuticals for MS, there is a need to
explore novel therapeutic avenues.
Testing a potential therapeutic option for MS
The effect of the gut microbiome on MS pathology is a promising avenue of
investigation. Therefore, characterizing the microbial profile of the MS gut as compared
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to healthy gut microbiomes, as well as other autoimmune diseases, could be insightful.
By investigating the structure of these microbiomes it is possible to understand what
microbes are contributing to the pro-inflammatory state and lack of anti-inflammation.
From this data, it is possible to then develop probiotic mixtures containing critical
bacterial populations, which can increase Treg numbers, but are diminished in the MS gut
microbiome.
Here, we propose to explore the bi-directionality between the etiology and
pathology of MS and the gut microbiome of the host. To achieve this goal, we will
analyze the structure and function of the gut microbiome when CNS inflammatory
demyelination is induced in EAE mice, and in healthy control mice. From there, we will
confirm the role the gut microbiome plays on symptoms of MS by subjecting EAE mice
to broad-spectrum antibiotics and assessing the clinical scores of these mice during
disease progression (as previously done in other models of EAE).47,48 From the data
obtained from the structural analysis of the EAE gut microbiome, we will test the
efficacy of a probiotic on the symptoms of EAE in mice.
We hypothesize that the gut microbiome of EAE differs between individuals
based on the severity of disease as well as the time point after disease induction. The
broad-spectrum antibiotic cocktail will reduce disease severity when mice are
subjected to the antibiotics during the early, more pro-inflammatory phase of EAE
as opposed to later stages of disease. Moreover, we also propose that the oral
treatment of EAE mice with a genetically-engineered probiotic strain of Lactococcus
lactis designed to promote anti-inflammatory responses will confer protection in the
severity of EAE.
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Chapter 2: Analyzing the Effect of CNS inflammatory demyelination on the
Composition of the Gut Microbiome using a murine model of Multiple Sclerosis
Introduction
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system
(CNS) MS in which the host’s immune cells degrade the myelin sheath of neurons. This
degradation is brought on by a breakdown in self-tolerance which allows the production,
mobility, and function of these auto-destructive immune cells.1 The exact mechanism of
why this phenomenon occurs is yet to be defined. However, it is believed that this could
be a result of a deficit in T regulatory cell (Treg) populations.1 Moreover, when therapies
targeting enhancement of defective Treg populations are applied in the murine model of
experimental autoimmune encephalomyelitis (EAE), symptoms of disease progression
are ameliorated.1 Seeing that the dysfunctional Tregs may play a critical role in MS
pathology, it is critical to explore what is causing the defect in Tregs.
Recently, researchers have begun to make the association between the defunct
Treg populations in MS and the changes in the gut microbiome. A recent study by
Cekanaviciute et al. showed that certain microbial taxa were diminished in MS patients
as compared to healthy individuals.2 More so, some of these reduced taxa are associated
with the expression of IL-10+FoxP3+ Tregs.2 Moreover, the gut microbiome of MS
patients can exacerbate the severity of EAE in murine models.2 For instance, MS
patient’s stool can cause spontaneous autoimmune encephalomyelitis in murine models.3
These results show the clear connection between the gut microbiome and its role in the
etiology of MS. Further understanding the potential mechanisms of this relationship is
required.
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The gut microbiome has been attributed several inflammatory conditions as well
as CNS disorders including MS.2-6 An investigation by Ochoa-Repáraz et al. showed that
the gut microbiome plays a role in disease pathology in the EAE model as well.7
Moreover, the gut microbiota regulates the function of regulatory immune cells and could
provide protection from EAE.7 Therefore, understanding the composition of the gut
microbiome in the EAE model could provide insight into avenues for novel therapeutics.
It is important first to characterize the gut microbiome at various points in EAE
progression as well as to compare the differences between gut microbiome compositions
in differing severities of disease.
The non-obese diabetic (NOD) mouse model of EAE is characterized by an early
stage of low grade disease severity followed by a more prolonged and exacerbated phase.
By being a longer more drawn out model of disease, it allowed us to analyze the gut
microbiome in a controlled fashion; it permitted for the composition of the gut
microbiome at various time points of the disease as well as the severity of the disease to
be analyzed. This makes the NOD model a more attractive model organism as opposed
to C57 or SJL strains. Further, in EAE studies, mice that suffer from milder forms of
disease are not evaluated exclusively; we aim to show structural and functional
differences between the mild form of EAE, the severe form of EAE, and mice no
subjected to EAE.
In this study, we hypothesize that the gut microbiome composition will differ
between the various stages of EAE progression in a murine model of disease already
established in the NOD mouse.8-10 Further, we also hypothesize that the gut microbiota
will differ depending on the severity of the disease. These alterations in gut microbiota
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will lead to altered metagenomic functions and potentially explain differing severities of
EAE. Our experimental aim is to provide evidence that the gut microbiota differs as a
function of disease status.
Materials and Methods
Mice and Treatments
Ten-week old female NOD ShiLt (NOD/ShiLt) mice obtained from the Jackson
Laboratories were utilized for the experiment. All aspects of animal use and care were
conducted in accordance with the institutional policies for animal health and well-being
under Eastern Washington University.
EAE induction
EAE was induced using Hooke KitTM for EAE induction (Hooke Laboratories,
EK-2110) containing 200 µg MOG35-55 emulsified in 200 µl of complete Freund’s
adjuvant (CFA). Each mouse was initially challenged with a single subcutaneous
challenge. On days 0 and 1 post-challenge, each mouse received 400 ng of Bordetella
pertussis toxin intraperitoneally (List Biological Laboratories, Campbell, CA; provided
with the Hooke KitTM for EAE induction). Mice were monitored and the disease
progression was scored daily by blinded observers as previously described: 0, clinically
normal; 0.5, limp tip of the tail (when picked up by the base of the tail, the tail still has
tension except for the tip); 1, limp tail (no tail tension observed); 1.5, limp tail and
inhibition of the hind legs with a slight wobble when the individual walks; 2, limp tail
and hind leg weakness, the wobble in each step is more pronounced, mouse exhibits poor
balance;2.5, limp tail, and the hind legs drag; mouse exhibits poor balance; 3, limp tail,
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hind legs exhibit complete paralysis, or limp tail with one front leg and one hind leg
exhibiting complete paralysis; 3.5, limp tail, hind legs exhibit complete paralysis, and
mouse can move, but if placed on its side it cannot right itself back up; 4, limp tail, hind
legs exhibit complete paralysis, the front legs are starting to show signs of paralysis, and
the mouse is moving minimally but still appears to be alert and eating; 5, limp tail, hind
legs exhibit complete paralysis, mouse exhibits minimal movement in front legs, and the
mouse expresses minimal or no reaction to contact.11 In accordance to IACUC policies,
mice exhibiting a score of 3.5 or higher were sacrificed with primary chemical euthanasia
via carbon dioxide asphyxiation followed by secondary physical euthanasia via cervical
dislocation. The first two days of concurrent scores of 0.5 or higher were considered and
documented as the onset of disease per individual. Type 1 diabetes will spontaneously
develop in NOD mice at week 14-20 of age unless CFA is administered.12-14 For
breeding purposes, we administered CFA to the breeding pairs to prevent the onset of
insulitis. Diabetic mice were not treated with CFA or MOG35-55.
Fecal pellet isolation and 16S rRNA sequencing
Aseptically, fecal pellets were collected on days 0, 14, 30, and 58 and were stored
at -80 oC. Samples were sent to AKESOgen (Norcross, GA) for 16S rRNA analysis of
the gut microbiome. Qiagen DNA stool extraction kits were used to isolate DNA. 1
ng/ml of DNA aliquots were analyzed using PCR with primers specific to the variable
region 4 (V4) of the prokaryotic 16S rRNA gene. Library preparation and sequencing for
V4 amplicon sequencing was performed on the Illumina MiSeq V2 (2 x 250bp)
chemistry. AKESOgen used a protocol that combined the 2-steps in 1-step of
amplification with forward primer (515F) and indexed reverse primer (806R). Once the
37

sequencing was performed, we used a cloud-based web application that facilitates the
analysis of microbiome data from the Office of Cyber Infrastructure and Computational
Biology (OCICB), National Institute of Allergy and Infectious Disease (NIAID).
Utilizing Nephele from the Nation Institute of Health (NIH)
(http://nephele.niaid.nih.gov/) in 2016 the data was analyzed using QIIME and R was
used for the statistical analysis.
A total of 60 samples were compared using the QIIME FASTQ paired end
protocol. Samples were pre-processed with a Phred quality score with a mean of 19 and
a 99% base pair accuracy was observed. Quality filters were applied to obtain a median
sequence length of 253.0 per sample. 23435 total observations were found. The
maximum and minimum number of counts obtained per sample were 573,715.0 and
174,345.0 respectively, with a mean of 287,059.183 +/- 75,305.628 (+/- the standard
deviation). Reads that were demultiplexed were clustered into OTUs open reference
approach by comparison with the Greengenes database allowing sequences clustered at
97% similarity. Analysis included the identification of chimeras with 6,119 chimeras
found and removed using UCHIME. The OTU table was rarified to 174,344 sequences
per sample. From the OTU table, the data was normalized for chromosomal redundancy
in QIIME and chromosomal data was collected from the Greengenes database per OTU
read. This generalized data was then assigned putative metagenomics functions based on
each OTU read. This data was set aside from the OTU table for further statistical
analysis in R.
The abundance of each taxa was analyzed using the phyloseq package in R.15 We
visualized the compositional heterogeneity of the microbial community of each sample at
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every time point of collection and at each taxonomical level using non-metric
multidimensional scaling (NMDS),16 the ordinate function in the phyloseq package and
the metaMDS function in the vegan package, and the Bray-Curtis dissimilarity Index.
We used 6 dimensions as it produced the lowest amount of stress, defined as the
difference between the original dissimilarity and the dissimilarity based on a simplified
combination of the original taxa.
Public access to raw sequences can be found at Sequence Read Archive (SRA) at
NCBI (BioProject ID: PRJNA383155).
Statistical Analysis
Area under the curve analysis followed by one-way ANOVA and multiple
comparisons tests were applied to show differences in EAE scores of no EAE, mild EAE,
and severe EAE mice. Weights were compared by two-way ANOVA followed by
multiple comparisons test. To compare severity index as well as the onset of disease,
Mann-Whitney tests were used. p-values < 0.05, <0.01, <0.001, and <0.0001 were
indicated. The effect of disease on the overall microbiota structure was visualized by
plotting the results by NMDS in 2 dimensions. Plots were obtained using the R vegan
package. After multiple iterations, the one showing the lowest stress was used to
generate visuals and for statistical permutational Multivariate Analysis of Variance Using
Distance Matrices, ADONIS,18 a permutational form of multivariate analysis of variance
(MANOVA). Since it is a permutational method, it produces slightly different p-values
each time. To obtain reliable p-values, we repeated the ADONIS method 10,000 times
and reported the average of those p-values for each taxonomical level, each time-point,
and each comparison (Table 2.2). Genus-level counts were compared using the non39

parametric Wilcoxon Rank-Sum test (when comparing 2 sample or matched samples)
(Fig. 2.4) Differences were considered significant with a p-value < 0.05. Putative
metagenomic functions assigned to the intestinal microbiota at each time point of fecal
collection was analyzed by two-way ANOVA followed by multiple comparisons test
(Table 2.3).
Results
We induced active EAE in 10 week-old female NOD mice as described
previously.8-10 EAE in NOD mice shows an incidence rate of disease of approximately
75%. In our study 31 out of the total 45 mice experimentally induced with EAE (68.9%)
showed symptoms of disease, which is similar to what has been previously described
(Fig. 2.1A, Table 2.1). The mice initially develop a short phase of disease with lower
clinical scores that progressed into more severe symptoms of EAE. These animals were
considered to be part of the severe EAE group. The other 14 mice (31.1% of the mice
experimentally induced with EAE) showed a milder form of the disease which can be
characterized by the initial mild disease severity that did not progress later into more
severe scores as seen in the severe EAE group. These mice exhibited average scores
much less than the severe EAE group and therefore considered to be the mild EAE group
(Fig. 2.1A, Table 2.1). One animal in the mild EAE group did exhibit a clinical score of
2 on day 34; however, it did not progress into a more severe form of EAE and therefore
was still considered in part of the mild EAE group.
Scores for both the severe EAE group as well as the mild EAE group exhibited an
initial phase of disease ranging from day 9 to day 35 with scores averaging between 0.5
and 1. At day 35, the clinical scores the severe EAE group progressed into the more
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severe clinical score range and did not exhibit any signs of remission. The mild EAE
group, however, did exhibit signs of a remission post day 35 (Fig. 2.1A). The area under
the curve was greater for the severe EAE group as compared to both the mild EAE group
as well as the no EAE group (Fig. 2.1B). The no EAE group were mice that were not
challenged with EAE and therefore exhibited no symptoms of EAE (Fig. 2.1A). There
also was no significant difference between the area under the curve for the no EAE group
and the mild EAE group (Fig. 2.1B). Even though the severity of the disease differed
between the severe EAE group and the mild EAE group, there was no difference in the
onset of EAE between these groups (Fig. 2.1C).
The body weights of every animal were monitored and recorded weekly. There
was no significant difference in body weight between all of the groups (data not shown).
However, when the percentage of the initial weight was compared based on the form of
disease that developed (mild vs. severe), we observed a significant decrease in weight
gain in the severe EAE group versus the no EAE control group (Fig 2.1D).
To assess whether or not disease severity affected the composition of the gut
microbiota, we longitudinally evaluated the mice at each time point of fecal pellet
collection (days 0, 14, 30, and 58 post EAE induction) and correlated this with the
severity of EAE symptoms for each mouse. These groups consisted, again, of the control
no EAE group, the mild EAE group, and the severe EAE group. The clinical scores at the
times of the collection are shown in Figure 2.2A. Of all the stool samples collected, we
analyzed 15 of the mice. We chose mice that were never caged with mice belonging to
mice of other experimental groups. To generate relative abundances on each taxonomical
level, 16S rRNA gene amplicon sequencing was used. To assess whether disease
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severity affected stool microbial composition, we analyzed the similarity between each
individual animal analyzed. To establish a genetic background baseline to compare
deviations in the stool microbial composition, we compared stool collected prior to EAE
induction on day 0. The analysis was conducted at the genus level by ordination analysis
using nonmetric dimensional scaling (NMDS) in 2 dimensions (Fig. 2.2B). We used the
NMDS combination that yielded the lowest stress. Stress is defined as deviations
between the original dissimilarity of samples generated after the simplified combination
of the original taxa levels. After the NMDS analysis, we used the ADONIS multivariate
non-parametric ANOVA and ran the ADONIS analysis with 10,000 permutations to
obtain a distribution of p-values per comparison. No significant differences were
observed between the groups at this time point of day 0 (p = 0.895) (Fig. 2.2 and Table
2.2). Further, when the groups were compared individually (no EAE vs. mild EAE, no
EAE vs. severe EAE, and mild EAE vs. severe EAE) there were no significant
differences observed (Table 2.2).
The Shannon diversity index, a measure of taxa richness and evenness, of the
stool samples isolated from mild EAE group on day 14 was higher when compared to the
no EAE group (Fig. 2.2C; p = 0.0267). It also showed a trend towards elevation (p =
n.s.) in the severe EAE mice when compared to the no EAE group (Fig. 2.2C). When
comparing the amount of observed taxa at the species level between severe EAE mice
and no EAE mice, there was a significant reduction at day 58 indicating that a lower level
of species was identified in EAE mice at the end of the experiment (Fig. 2.2C; p =
0.0234).
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We next compared the overall composition of the gut microbiome of the three
different groups on days 14, 30, and 58 at the genus level as well by 2-dimesional NMDS
(Fig. 2.3A and Table 2.2). We started by comparing day 0 for the control no EAE group
with days 14, 30, and 58. We noted no significant difference between the gut
microbiome composition at these various time points (day 0 vs. day 14: p = 0.0961; day 0
vs. day 30: p = 0.0960; day 0 vs day 58: p = 0.0962). This was also true when comparing
day 14 with day 30 and day 58 both with p-values of 0.0962 (graph not shown).
When comparing the taxa at the genus level on day 14, there were significant
differences between the overall compositions of the gut microbiome between the control
no EAE group, the mild EAE group, and the severe EAE group (p = 0.0034) (Fig. 2.3A
and Table 2.2). This was also the case between the compositions on day 30 (p = 0.0096)
(Fig. 2.3A and Table 2.2). However, there were no significant differences between the
groups on day 58 (p = 0.1915) (Fig. 2.3A and Table 2.2). When analyzing the gut
microbiome between groups at day 14, there were still significant differences; no EAE
group vs. mild EAE group (p = 0.0406) and no EAE group vs. severe EAE group (p =
0.0167) (Table 2.2). Further, on day 14 there also was a significant difference between
the structure of the gut microbiome of the mild EAE group vs. the severe EAE group (p =
0.0327) (Table 2.2).
On day 30, there also was significant differences between the gut microbial
composition of the control no EAE group vs. the severe EAE group (p = 0.0168) and
between the mild EAE group vs the severe EAE group (p = 0.0407) but not between the
control no EAE group vs. the mild EAE group (p = 0.3183) (Table 2.2). At day 58 postEAE induction there were no overall differences between the three groups (p = 0.1915)
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(Fig. 2.3A and Table 2.2). Similar NMDS analyses and statistical comparison were run
at every taxonomical level but no significant differences were seen between the gut
microbial compositions on day 58 (not shown). From these results we do believe that
EAE does in fact alter the composition of the gut microbiome in NOD mice. Further, the
extent of disease itself seems to alter the composition as well; this is clearly seen when
examining the severe EAE group vs. the mild EAE group and then further the control no
EAE group vs. the mild EAE group.
We next compared the effects of disease progression and severity on the relative
abundance of genera among the major phyla. The relative abundances at the genus level
are shown in Figure 2.3B (average relative abundances for the n = 5 per group and time
point). We observed changes in genus-level sequence counts of gut microbiota primarily
in the early stages of disease. An undetermined genus of the family Ruminococcaceae
and the genus Akkermansia from the family Verucomicrobiaceae were increased in the
severe EAE group vs. the control no EAE group. The undetermined genus of the family
Ruminococcaceae differed between the control no EAE group vs. the severe EAE group
at day 14 (raw p = 0.008, adj. p = 0.17) (Fig. 2.4). The genus Akkermansia differed
between the control no EAE group vs. the severe EAE at day 14 as well (raw p = 0.031,
adj. p = 0.57) (Fig. 2.4). The opposite was seen with an undetermined genus of the
family Christensenellaceae the genus Lactobacillus of the family Lactobacillaceae, in
which there was a decrease in sequence counts for these taxa between the severe EAE
group vs. the control no EAE group. The undetermined genus of the family
Christensenellaceae differed between the control no EAE group vs. the severe EAE
group at day 14 (raw p = 0.008, adj. p = 0.22) (Fig. 2.4). The genus Lactobacillus
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differed between the control no EAE group vs. the severe EAE at day 14 as well (raw p =
0.008, adj. p = 0.17) (Fig. 2.4).
When taken together, our results for the retrospective analysis of stool from mice
suffering from various severities of EAE show that the extent of disease as well as time
point during disease progression alters the structure of the gut microbiome. Moreover,
these alterations can have a direct impact on specific bacterial taxa. These changes,
however, are short lived and occur primarily in early more inflammatory stages of
disease. Due to the limited number of samples compared, it is possible that our data
would preclude to put statistical significance on these changes, although interesting
trends that require further study were observed.
Using putative metagenomics reads based on using the PICRUSt algorithm
showed differing functionality in the gut microbiome based on what taxa were altered
(Fig. 2.5). The heat-map generated shows that metagenomics functions differed in the
severe EAE group, but did not in the mild EAE group or the no EAE group.
Metagenomic function irrelevant to bacterial function were not included (Fig. 2.5).
Further, metagenomic functions between the various time points of disease were analyzed
using two-way ANOVA followed by multiple comparisons test (Table 2.3). Significance
under a p-value of 0.05 were noted in red. Taking data from disease severity and stage of
disease, amino acid metabolism and carbohydrate metabolism were further analyzed
based on disease severity from stool collected on day 14 (Fig. 2.6).
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Discussion
The understanding of how important the gut microbiome is in context to disease
has increased dramatically in recent scientific history. Our work as well as others
highlights just how important the immunomodulatory nature of the gut microbiome,
particularly the bacteria, is in the case of progression for experimental animal models of
CNS autoimmunity.
In this experiment, we show and characterize just how disease itself (specifically
EAE) alters the gut microbiome. Our results indicated that gut microbiota altered early in
mice that developed EAE as opposed to those that did not. Statistical analyses were
unable to detect specific deviations in specific bacterial genera associated with diseaseinduced dysbiosis. The trends show preliminary data that specific taxa that exhibit
immunomodulatory effects as well as regulate disease progression are affected. The
genus Lactobacillus was reduced (raw p = 0.008, adjusted: n.s.). Lactobacillus is known
for promoting immunomodulation and a mixture of Lactobacillus spp. has been shown to
promote protection against EAE in mice.19 This reduction in Lactobacillus could have a
profound impact on disease severity as well as progression. Another genus that was
reduced in the severe EAE mice was Christensenellaceae. Very little is known about the
functionality of Christensenellaceae and its role in the gut microbiome. This, in turn,
makes it quite interesting that it was reduced in the EAE murine model. On the other
hand, the genus Akkermansia as well as an unspecified genus of the family
Ruminococcaceae were increased in the severe EAE mice. Interestingly enough, a study
reported that the fecal transplantation of stool from MS patients into mice caused the
spontaneous development of EAE.3 The stool obtained from those MS patients had
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elevated levels of Akkermansia as well.3 These findings are interesting especially when
considered in the context to our study.
Additionally, we explored how alterations in gut microbiota would impact how
the gut microbiota functions. To do this, we utilized PICRUSt as part of the pipeline
analysis through Nephele by the NIH. Part of the analysis generated metagenomics reads
that could be quantified between the experimental groups. The severe EAE group had a
different function when compared to the mild EAE group and no EAE group (Fig. 2.5).
Additionally, the difference between microbiome function was noted specifically during
day 14 post EAE induction (Table 2.3). We then further were interested in amino acid
metabolism as well as carbohydrate metabolism due to their immunogenic importance.
We noted that there was an increase in gene expression for amino acid metabolism and
carbohydrate metabolism in the severe EAE group when compared to the mild EAE
group and the control group.
The data generated from PICRUSt is putative, but it provides interesting insight to
how disease severity and disease progression alters the gut microbiome. The
composition of the gut microbiome appears to be heavily influenced by both disease
severity as well as the time point post disease induction. These structural changes have a
profound impact on the way the gut microbiome can then function; by reducing bacterial
populations such as Lactobacillus, but increasing Akkermansia, there appears to be
changes in how the community behaves. These perturbations in the gut microbiota must
have some immunomodulatory impact that might be increasing the extent of
inflammation in the CNS. It is unfortunate, however, that the data generated by PICRUSt
is speculative, but the data can be a used to design further studies. In this experiment, we
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noted an increase in amino acid metabolism. This could hold some functional importance
due to the fact that gamma-aminobutyric acid (GABA) is a derivative of amino acids, and
its production is dependent on the gut microbiota.20 Moreover, GABA levels has also
been noted to be reduced in MS patients. Additionally, our lab is currently evaluating the
effects of GABA on EAE and determining its efficacy in reducing disease severity;
although speculative, perhaps the increase in amino acid metabolism could be reducing
GABA levels in the EAE mice.
In conclusion, this study aimed at exploring the extent in which EAE altered the
composition of the gut microbiome in NOD mice. This experiment further strengthens
the notion that the gut microbiome plays a critical role in disease pathology.
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Figures and Tables

Table 2.1. Number of mice used, number and percentage of mice that developed mild and severe
EAE, and day of disease onset.

Figure 2.1. Active EAE induces a progressive CNS disease in mice. EAE was induced in NOD
mice with a subcutaneous injection of MOG35-55 emulsified in CFA and 2 doses of pertussis toxin
(day 0 and 1) given intraperitoneally. Disease was induced in a total of 45 mice in 3 independent
experiments. 25 NOD mice were used as controls (no EAE). A) Graph depicts EAE clinical
scores using a 0-5 scale from one of 3 experiments performed (no EAE n = 5; EAE-induced, n =
15). Scores were compared by one-way ANOVA analysis followed by multiple comparisons test
(no EAE vs. mild EAE, mild EAE vs. severe EAE, and no EAE vs. severe EAE: p < 0.001). B)
Graphs indicate the area under the curve pf the clinical scores of all mice from the 3 experimental
groups: no EAE n = 25, mild EAE n = 14, and severe EAE n = 31 mice. The area under the
curves were compared by one-way ANOVA followed by multiple comparisons test. C) Day of
EAE onset for all mice from the 3 experimental groups, mild EAE n = 14 and severe EAE n = 31
mice, compared by student’s t-test. D) Body weights of no EAE, mild EAE, and severe EAE mice
from one of the three experiments performed (no EAE n = 5, mild EAE n = 5, severe EAE n =
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10). Percentages of body weights were compared by two-way ANOVA followed by multiple
comparison test (no EAE vs severe EAE: ***, p < 0.001).

Figure 2.2. Composition of the microbiome at day 0, α diversity and species richness during
disease. Stool samples analyzed from no EAE control mice (n = 5), mice that developed mild
disease (n = 5), and mice that developed severe EAE (n = 5). A) Samples were collected from all
NOD mice. Clinical scores (mean +/- SEM) of mice at each time point of fecal collection (day 0,
14, 30, and 58 post-EAE induction) were compared by two-way ANOVA. B) To examine the
compositional heterogeneity of the microbial communities found in the three groups, we used
non-metric dimensional scaling (NMDS) in R to ordinate the microbial communities of samples
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based on the Bray-Curtis dissimilarity index using QIIME after the 16S rRNA gene sequencing
analysis of stool samples, using the phyloseq package. Shown are the NMDA graph for the genus
taxonomical level of OTUS identified in the analysis at day 0. The statistical comparison was
performed using the permutational Multivariate Analysis of Variance Using Distance Matrices,
ADONIS, in the vegan package. C) Shannon index of α diversity and observed species measure
in the 3 experimental groups compared by one-way ANOVA.

Table 2.2. Averages of the p-values obtained after 10,000 different ADONIS analysis of NMDS
graphs for the genus level shown in Fig. 2 and 3A.

Figure 2.3. Early stages of EAE significantly affect the overall composition of the gut
microbiome. A) NMDS analysis for the genus taxonomical level of OTUs identified in the
analysis at day 14, 30, and 58. B) Relative abundances observed in analysis of the gut microbiota
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at the genus level. The bar graph represents the average of relative frequencies per group (n = 5)
per time point for abundances equal or above 1%.

Figure 2.4. Taxonomical differences between the no EAE, mild EAE, and severe EAE groups.
OTUs observed were compared at the genus level using the non-parametric Wilcoxon Rank-Sum
test was used.
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Figure 2.5. A heat-map was generated based on the magnitude of metagenomics reads based on
disease severity from pellets obtained on day 14 post EAE induction. From the fecal pellets, 16S
rDNA amplicon sequencing was performed and OTUs were generated using Nephele through the
NIH. Additionally, PICRUSt annotations of putative metagenomics function were applied to the
OTUs after being normalized.
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Table 2.3. Metagenomic functions differed on day 14 post EAE induction. Utilizing PICRUSt,
metagenomic annotations obtained from mice on day 0, day 14, day 30, and day 58 were
generated. Using two-way ANOVA followed by multiple comparisons test, each metagenomics
function was analyzed. Significance was considered for p-values below 0.05 and are denoted in
red.
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Figure 2.6. Carbohydrate and amino acid metabolism differed between the severe EAE group on
day 14. Using two-way ANOVA followed by multiple comparisons test, significance was noted
(p < 0.05).
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Chapter 3: Exploring Outcomes of Altering the Gut Microbiome in a murine model of
Multiple Sclerosis
Introduction
The use of antibiotics to target the gut microbiome for therapeutic merit has been
explored in the case Type 1 Diabetes, Fulminant Ulcerative Colitis, and experimental
autoimmune uveitis.1-3 Utilizing antibiotic cocktails to modulate intestinal microbiota
caused changes in disease severity. In the model of experimental autoimmune uveitis, the
expression of CD4+Foxp3+ Treg cell populations was increased while a reduction in IL17 producing Th17 cells was observed.3 These results, especially in the case of
experimental autoimmune uveitis, suggests insight that antibiotic interventions may
confer protection against symptoms of EAE, a model disease for MS, in NOD mice.
Increased levels of Th17 cells and reduced levels of Tregs have also been noted in MS.4,5
EAE has previously been explored in the context of antibiotic intervention. A
study by Ochoa-Repáraz et al. demonstrated that broad-spectrum antibiotic interventions
disrupted the balance between pro- and anti-inflammatory responses by modulating Treg
cell populations.6 Additionally, Yokote et al. reported similar findings but in Natural
Killer T cell populations.7 These experiments analyzed the impact of antibiotic
intervention on modulation of EAE in SJL as well as C57 mice. However, to the best of
our knowledge, the impact of antibiotics on symptoms of EAE in NOD mice remains
unknown.
NOD mice demonstrate a more chronic, long-term version of EAE whereas SJL
and C57 mice exhibit a short, yet severe, course of EAE. By utilizing NOD mice as
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opposed to SJL or C57 mice, it is possible to elucidate the impact intestinal microbiota
plays at various points in EAE progression. Additionally, utilizing NOD mice could also
provide novel insight into a potential therapeutic window for disease modulation; by
demonstrating when antibiotics have the most prominent effect on disease progression, it
is possible to infer the ideal time point in which therapeutics could have the most
beneficial effect.
We propose to explore the role antibiotic intervention plays on EAE modulation
at various time points of disease. Because of the heightened inflammation occurring in
the early stages of EAE, we hypothesize that early antibiotic intervention would have the
highest beneficial impact on disease severity. The later stages of EAE are defined as
being more neurodegenerative and therefore antibiotic interventions during the middle
and late stages of EAE are predicted to have lower impacts on modulating EAE severity.
Further, it is also hypothesized that antibiotic interventions would increase Treg cell
populations based on evidence obtained from Ochoa-Repáraz et al. in 2009.6
Materials and Methods
Mice and Treatments
Ten-week old female NOD ShiLt (NOD/ShiLt) mice obtained from the Jackson
Laboratories were utilized for the experiment. All aspects of animal use and care were
conducted in accordance with the institutional policies for animal health and well-being
under Eastern Washington University.
Mice subjected to oral antibiotic treatment were given drinking water with
neomycin (1 g/L) (Fischer Bioreagents, BP2669-25), vancomycin (0.5 g/L) (Fischer
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Bioreagents, BP2958-1), metronidazole (1g/L) (Acros Organics, 210340050), and
ampicillin (1 g/L) (Fischer Bioreagents, BP1760-25) for 2 weeks. Control mice received
standard drinking water, and three different treatment windows were used depending on
the experiment: 1) day 0 of EAE induction to day 14. 2) day 30 to day 44, or 3) day 69 to
day 83. Body weights were measured on day 0 of EAE induction (at the initiation of
treatment with antibiotics), every 3 days during antibiotic treatment, and weekly
following the termination of antibiotic treatment.
EAE induction
EAE was induced using the Hooke KitTM for EAE induction (Hooke Laboratories,
EK-2110) containing 200 µg MOG35-55 emulsified in 200 µl of complete Freund’s
adjuvant (CFA). Each mouse was initially challenged with a single subcutaneous
challenge. On days 0 and 1 post-challenge, each mouse received 400 ng of Bordetella
pertussis toxin intraperitoneally (List Biological Laboratories, Campbell, CA; provided
with the Hooke KitTM for EAE induction). Mice we monitored and the disease
progression was scored daily as previously described: 0, clinically normal; 0.5, limp tip
of the tail (when picked up by the base of the tail, the tail still has tension except for the
tip); 1, limp tail (no tail tension observed); 1.5, limp tail and inhibition of the hind legs
with a slight wobble when the individual walks; 2, limp tail and hind leg weakness, the
wobble in each step is more pronounced, mouse exhibits poor balance;2.5, limp tail, and
the hind legs drag; mouse exhibits poor balance; 3, limp tail, hind legs exhibit complete
paralysis, or limp tail with one front leg and one hind leg exhibiting complete paralysis;
3.5, limp tail, hind legs exhibit complete paralysis, and mouse can move, but if placed on
its side it cannot right itself back up; 4, limp tail, hind legs exhibit complete paralysis, the
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front legs are starting to show signs of paralysis, and the mouse is moving minimally but
still appears to be alert and eating; 5, limp tail, hind legs exhibit complete paralysis,
mouse exhibits minimal movement in front legs, and the mouse expresses minimal or no
reaction to contact.8 In accordance with IACUC policies, mice exhibiting a score of 3.5
or higher were sacrificed with primary chemical euthanasia via carbon dioxide
asphyxiation followed by secondary physical euthanasia via cervical dislocation. The
first two days of concurrent scores of 0.5 or higher were considered and documented as
the onset of disease per individual. Type 1 diabetes will spontaneously develop in NOD
mice at week 14-20 of age unless CFA is administered.9-11 For breeding purposes, we
administered CFA to the breeding pairs to prevent the onset of insulitis. Diabetic mice
were not treated with CFA or MOG35-55.
Cell preparation and flow cytometry
Single cell lymphocyte preparations from Peyer’s patches were stained using
conventional methods. A live/dead fixable fluorescence-labeled viability dye (BD
Biosciences, 564407) was used in all staining protocols, and samples were gated on
viable cells for subsequent analysis. Cell subsets were analyzed using fluorochromeconjugated mAbs against T cell antigens CD3 (BD PharMingen, 553062), CD4 (BD
PharMingen 553052), and CD39 BioLegend, 143804). Intracellular staining for Foxp3
was performed using fluorochrome labeled anti-Foxp3 mAb (clone FJK-16s;
eBioscience, 175773-82). Flow cytometric results were acquired using BD Accuri C6
(BD Biosciences, San Jose, CA). Data was analyzed using FloJo software (FloJo LLC.,
Ashland, OR).
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Statistical analysis
Parametric and non-parametric t-tests and one-way ANOVA followed by the KruskalWallis comparisons of multiple groups was applied to show differences in flow
cytometric analysis. Two-way ANOVA followed by multiple comparisons tests were
used to compare the scores of EAE and EAE-ABX mice. In addition, area under the
curve analysis followed by Mann-Whitney tests were used to compare scores of EAE and
EAE-ABX mice. Weights were compared by two-way ANOVA followed by multiple
comparisons test. To compare severity index, the Mann-Whitney test was used (p-values
< 0.05, <0.01, <0.001, and <0.0001 were indicated).
Results
Previous work has documented the effects of the gut microbiota in regard to regulating
the progression of acute EAE when SJL and B6 mice were treated orally with broad
spectrum antibiotics before the induction of EAE.6,7 Ochoa-Repáraz et al. showed that
treatment with broad-spectrum antibiotics altered the balance of regulatory and proinflammatory responses in mice with EAE and that regulatory T cells (Tregs) were
responsible for the protection achieved via microbiota modulation.6 Nakamura et al.
showed similar results in the case of the autoimmune uveitis.3 Additionally, Yokote et al.
reported similar findings but suggested that a different cell population was responsible.7
Our experiment wanted to evaluate whether broad-spectrum antibiotics would affect the
progression of the secondary, more severe, stages of EAE in NOD mice. The average
clinical scores of the antibiotic treated mice were significantly reduced at multiple time
points after day 40 (Fig. 3.1A). Analyzing the area under the curves showed a significant
reduction in clinical scores of mice treated with the antibiotic cocktail when compared to
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control mice (Fig. 3.1B; p = 0.0162). Additionally, the treatment with antibiotics also
delayed the onset of disease (Fig. 3.1C; p = 0.0005) and reduced the overall severity
index when compared to control mice (Fig. 3.1D; p = 0.008). Because of the unintended
impacts to animal health from broad-spectrum antibiotic exposure, the weight of each
animal was monitored weekly. At day 6 of treatment, we observed a significant
reduction in body weight of antibiotic treated mice when compared to control mice (Fig.
3.1E). At day 10, the weights recovered and no overall significant differences were
observed when comparing the area under the curve (not shown; p = 0.7295). Flow
cytometric analysis showed that the frequency of Foxp3+ Tregs increased in the Peyer’s
patches during EAE (Fig. 3.1F). We also noticed similar increases in CD39+ T cells as
well as Foxp3+CD39- Tregs.
We then compared the ability of orally administered broad-spectrum antibiotics to
reduce the severity of EAE when administered after the onset of disease. Using mice that
survive the initial wave of CNS inflammation, we treated mice with antibiotics from day
30 to day 44 or day 69 to day 83 post EAE challenge. Again, control mice received
normal drinking water. As a whole, the mice that received antibiotics during later stages
of disease showed a mild improvement in clinical scores, but the difference was not
statistically significant (Fig. 3.2). This indicates that early intervention of gut microbiota
manipulation can affect the progression of EAE in NOD mice.
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Discussion
Our work, as well as others, highlights just how important the immunomodulatory
nature of the gut microbiome, particularly the bacteria, is in the case of disease
progression for experimental animal models of autoimmunity. In this experiment, we
evaluated the gut microbiome and how it modulates the severity of disease (in this case,
EAE).
Our results indicate that disease progression is significantly altered when mice
received broad-spectrum antibiotics orally. Two weeks of treatment also significantly
delayed the onset of EAE as well (Fig. 3.1). Moreover, despite the long nature of EAE in
NOD mice, the short therapeutic window of the early stages of disease can reduce the
severity of the second phase of disease when intervention is undertaken early in disease
development. This is logical in the context of the composition of the gut microbiome, as
well as more inflammatory nature of the first phase of EAE.12 The second phase of EAE
in NOD mice is more neurodegenerative and, therefore, later therapeutic intervention
with antibiotics would be predicted to have a diminished impact on disease modulation.12
We observed that antibiotic intervention at later time points of the disease (day
30-44 as well as day 70-84) did not have a significant impact on disease severity (Fig.
3.2). This is largely attributable to the fact that alterations in the gut microbiome are not
as large or important at this stage of disease. In one study, on day 58 post EAE induction
in NOD mice there was no significant differences in the gut microbiota structure between
severely ill EAE mice, mildly ill EAE mice, and mice not subjected to EAE.12 This may
reflect the observation that, at this point, the inflammatory phase of disease has passed,
and thus is logical that altering the gut microbiome would have no major impact on
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disease severity; at this point, the onset of neurodegeneration is underway. Additionally,
we demonstrated that the functional differences in the gut microbiome were noted on day
14 post EAE induction as opposed to day 30 or day 58. This further supports the notion
that the antibiotics were unlikely to have a profound effect on disease modulation during
late stages of disease.
In conclusion, this study was geared to explore the extent in which the gut
microbiome modulates disease in NOD mice. This experiment further strengthens the
notion that the gut microbiome plays a critical role in disease pathology.
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Figures and Tables

Figure 3.1. Early treatment with antibiotics reduces the severity of EAE in NOD mice. EAE was
induced in NOD mice that were treated with antibiotics administered in the drinking water from
day 0 to 14 or given normal drinking water as a control. A) EAE clinical scores are shown from
one or two independent experiments (n = 5), for a total of n = 8 per group. Comparisons were
made using a two-way ANOVA followed by multiple comparisons test (*, p < 0.05). Graphs
indicate the area under the curve as calculated by Prism (B; n = 5 for the experiment depicted in
panel A), the day of EAE onset (C), and the severity index (D). Panels C and D depict values
obtained for all mice combined between the 2 experiments (n = 8). Significance was measured
using Mann-Whitney test. E) Body weights shown from one or two independent experiments for
a total of n = 8 per group. Two-way ANOVA followed by multiple comparisons test (**, p <
0.01; ***, p < 0.001). F) Graphs indicate frequencies of Tregs using flow cytometric analysis of
live CD4+ T cells in the Peyer’s patches based on expression of Foxp3 and CD39 (n = 5 per
group). Comparisons were made using a two-way ANOVA followed by multiple comparisons
test (*, p < 0.05; **, p < 0.001).
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Figure 3.2. Late treatments with antibiotics does not reduce the severity of EAE in NOD mice.
EAE was induced in NOD mice that were treated with antibiotics administered in the drinking
water from day 30 to day 44 as well as day 70 to day 84. A) EAE clinical scores are shown
from one or two independent experiments (n = 5), for a total of n = 8 per group. Two-way
ANOVA followed by multiple comparisons test. Graphs indicate the area under the curve as
calculated by Prism (B; n = 5 for the experiment depicted in panel A). Significance was measured
using Mann-Whitney test. C) EAE clinical scores are shown from one or two independent
experiments (n = 5), for a total of n = 8 per group. Two-way ANOVA followed by multiple
comparisons test. Graphs indicate the area under the curve as calculated by Prism (C; n = 5 for
the experiment depicted in panel D). Significance was measured using the Mann-Whitney test.

71

Chapter 4: Assessing the protective effects of an anti-inflammatory, genetically
modified, Probiotic strain of Lactococcus lactis in a murine model of Multiple Sclerosis
Introduction
Tolerance is the control that our immune system has in the balance between
overactive or underactive immune cells. The immune system also must balance
inflammatory responses and anti-inflammatory responses, in conjunction with tolerance,
to ensure that the body only attacks foreign or pathogenic material but not the residential
microbes or self-components. If these mechanisms fail, the result is autoimmunity.
Autoimmune diseases are diseases in which an exaggerated immune response eventually
leads to immune system failure and an inability to distinguish self from non-self. The
microbiome has a clear relationship with the immune system by influencing the balance
of immune responses that control autoimmune diseases1; the immune system and
autoimmune diseases share a bidirectional relationship with the gastrointestinal bacteria
in an individual.2 The disease state shapes the biodiversity and composition of
gastrointestinal bacteria, and these bacteria help regulate and modulate the host’s immune
system.1
Using a MS model known as Experimental Autoimmune Encephalomyelitis
(EAE) in Non-Obese Diabetic (NOD) mice, we previously showed that disease
progression is associated with reduction in certain microbial taxa.2 When antibiotics
were orally utilized after 14 days post disease induction, the disease severity was
attenuated.2 When the gut microbial composition was analyzed, there was a severe
reduction in Lactobacillales found in the guts of non-treated micel This suggests a
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connection between the gut microbiome and autoimmune diseases as a bi-directional
relationship.
In terms of treatment options for relapse-remitting MS (RRMS) patients, there are
commercial drugs already available. However, therapeutics are not efficacious enough
and come with a wide range of mild to severe side effects. Furthermore, there currently
are no options available for secondary progressive MS (SPMS) treatment.3 Thus, new
and safer treatment options are needed. Our preliminary data suggests a focus on the
order Lactobacillales would be prudent, since it is reduced significantly during an early
therapeutic window.4,5
Previous experiments have been performed to induce oral tolerance, or
immunomodulation, via the oral introduction of antigens.4-6 Kasarello et al. used
Lactococcus lactis to deliver self-antigens by inserting the genes into the L. lactis
bacterium and found evidence that this methodology is useful for promoting oral
tolerance.5 What is problematic, however, is that this experiment also used self-antigens
from myelin tissue.5 In a clinical setting there is a reason of concern with the notion of
treating MS patients with a self-antigen which could induce harm, and likely would not
gain IRB-approval. By engineering the expression of CFA/I fimbria, we eliminate the
use of self-antigens for oral tolerance and provide a novel and safe approach to achieving
oral tolerance.
Because of the potential connection between the reduction in disease severity and
the presence of Lactobacillus, MS becomes a target disease to investigate using
Lactobacillus. The Pascual laboratory at the University of Florida, has developed a
genetically modified form of Lactococcus lactis to express a Colonizing Factor Antigen I
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(CFA/I) fimbriae which has been shown to confer protection from other autoimmune
diseases such as rheumatoid arthritis.7 MS has not been explored with this approach.
CFA/I fimbriae modulates the immune system by inducing T regulatory cells (Tregs) in
an ectoenzyme CD39 dependent fashion.8 This immunomodulatory induction of Tregs
by the CFA/I fimbriae is a central focus of our current design. Choosing the CFA/I
fimbriae as a target antigen is ideal since the antigen is foreign and non-myelin in nature.
We intend to utilize the CFA/I genetically modified L. Lactis bacterium to induce oral
tolerance by performing oral gavage on EAE mice during the therapeutic window in
which the presence of Lactobacillus is known to be reduced. We propose to explore the
immunomodulation of SPMS in the C57 murine model via utilization of a predesigned
probiotic Lactococcus lactis–CFA/I (L. lactis-CFA/I). We hypothesize that the oral
treatment of L. lactis–CFA/I will reduce the severity of disease in EAE mice (reduced
EAE scores).
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Materials and Methods
Mice and Treatments
Ten-week old female NOD C57BL/6 mice obtained from the Jackson
Laboratories were utilized for the experiment. All aspects of animal use and care were
conducted in accordance with the institutional policies for animal health and well-being
under Eastern Washington University.
EAE induction
EAE was induced using Hooke KitTM for EAE induction (Hooke Laboratories,
EK-2110) containing 200 µg MOG35-55 emulsified in 200 µl of complete Freund’s
adjuvant (CFA). Each mouse was initially challenged with a single subcutaneous
challenge. One days 0 and 1 post-challenge, each mouse received 400 ng of Bordetella
pertussis toxin intraperitoneally (List Biological Laboratories, Campbell, CA; provided
with the Hooke KitTM for EAE induction). Mice we monitored and the disease
progression was scored daily as previously described: 0, clinically normal; 0.5, limp tip
of the tail (when picked up by the base of the tail, the tail still has tension except for the
tip); 1, limp tail (no tail tension observed); 1.5, limp tail and inhibition of the hind legs
with a slight wobble when the individual walks; 2, limp tail and hind leg weakness, the
wobble in each step is more pronounced, mouse exhibits poor balance;2.5, limp tail, and
the hind legs drag; mouse exhibits poor balance; 3, limp tail, hind legs exhibit complete
paralysis, or limp tail with one front leg and one hind leg exhibiting complete paralysis;
3.5, limp tail, hind legs exhibit complete paralysis, and mouse can move, but if placed on
its side it cannot right itself back up; 4, limp tail, hind legs exhibit complete paralysis, the
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front legs are starting to show signs of paralysis, and the mouse is moving minimally but
still appears to be alert and eating; 5, limp tail, hind legs exhibit complete paralysis,
mouse exhibits minimal movement in front legs, and the mouse expresses minimal or no
reaction to contact.9 In accordance to IACUC policies, mice exhibiting a score of 3.5 or
higher were sacrificed with primary chemical euthanasia via carbon dioxide asphyxiation
followed by secondary physical euthanasia via cervical dislocation. The first two days of
concurrent scores of 0.5 or higher were considered and documented as the onset of
disease per individual.
Preparation of Lactococcus lactis and Oral Gavages
For the experiment, two genetically modified strains of Lactococcus lactis were
obtained from the Pascual laboratory at the University of Florida. The pBzMM153 strain
(Lactococcus lactis expressing the CFA/I fimbriae) (L. lactis - CFA/I) and pMSP3535H3
strain (Lactococcus lactis not expressing CFA/I fimbriae but containing the same plasmid
vector) (L. lactis empty) were grown at 30oC in DIFCO M17 broth supplemented with
0.5% glucose with 10µg/mL of erythromycin in a 25 mL flask. The strains were frozen
in 100 µL aliquots for subsequent gavages.
For the gavage treatments, a pre-inoculum was made of 6 mL of M17 DIFCO
broth supplemented with 0.5% glucose and 1.2µL of erythromycin at a concentration of
50mg/mL. The pre-inoculum was inoculated with one 0.1mL aliquot previously frozen.
The pre-inoculum was incubated overnight at 30oC overnight without shaking. The next
morning 3 mL of the pre-inoculum was introduced to 50 mL of pre-warmed fresh M17
DIFCO broth supplemented with 0.5% glucose and 1.2µL of erythromycin at a
concentration of 50mg/mL. The solution was allowed to incubate at 30oC until the
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optical density was approximately 0.2 to 0.23. Subsequently, 100µL of nisin was added
and the bacteria was allowed to incubate for 4 additional hours at 30oC. The approximate
CFU level for both L. lactis strains was approximately 30-60 x107 per mL.
Prior to receiving treatment, each mouse was orally gavaged with sodium
bicarbonate to neutralize the stomach pH and ensure the L. lactis would survive past the
stomach and enter the intestines. Subsequently, mice received 5 x 108 CFU of either L.
lactis - CFA/I, L. lactis empty, or sham (no L. lactis) on day 0, 3, and 7 post EAE
induction, respectively.
Statistical Analysis
Two-way ANOVA analysis followed by multiple comparisons test was used to
evaluate clinical scores on a daily basis. We compared L. lactis - CFA/I vs. control
(sham), L. lactis - CFA/I vs. L. lactis unmodified vector, and L. lactis unmodified vector
vs. control (sham) daily. To compare severity index, a one-way ANOVA analysis
followed by multiple comparisons test was conducted (p-values < 0.05, <0.01, <0.001,
and <0.0001 were indicated).
Results
Lactococcus lactis Expressing the CFA/I antigen confers long-term protection
against EAE in C57BL/6 Mice
To assess the efficacy of each treatment in comparison to control (mice received
PBS solution), we collected clinical scores of disease severity for each mouse every day
during the progression of disease. Both the L. lactis - CFA/I as well as the L. lactis
empty reduced the severity of EAE in mice (Fig. 4.1A). There were significant
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differences between the control mice and the L. lactis - CFA/I mice starting on day 10 (p
< 0.05) (Fig. 4.1A). Although statistical significance between disease severity in the
control mice and the L. lactis - CFA/I mice was lost at day 18, statistical significance was
observed at the termination of the experiment (p < 0.001) (Fig. 4.1A). From this data, we
infer that L. lactis - CFA/I conferred long-term protection against EAE that remained
throughout the experiment even when treatment ended on day 7 post EAE induction.
Additionally, there was statistically significant differences between the control
mice and the L. lactis empty mice starting at day 11 (p < 0.05) (Fig. 4.1A). Statistical
significance was lost between the control mice and the L. lactis empty mice on day 14,
but returned for a few days on day 24 (p < 0.005) (Fig. 4.1A). Ultimately, there was no
significant difference between the control mice and the L. lactis empty mice at the end of
the experiment (Fig. 4.1A). This suggests that there was a degree of protection conferred
by the L. lactis with an unmodified plasmid but the protection was short-term, especially
when compared to the L. lactis - CFA group. On day 28, there was a statistically
significant difference between the clinical scores of the L. lactis empty mice when
compared to the L. lactos - CFA/I mice (p < 0.05) (Fig. 4.1A).
The extent of disease severity in each treatment group was evaluated with pie
charts (Fig. 4.1B). Inside each treatment group, mice we grouped by clinical scores
ranging from 0-1, 1.5-2, 2.5-3, and 3.5-5. Visually, there are differences between the
distributions of disease severity in the three treatment groups. The L. lactis - CFA group
had scores in the 0-1 range throughout the entire experiment whereas the L. lactis empty
group no longer had mice with scores of 0-1 on day 28 (Fig. 4.1B). Interestingly, the
control group lost individuals with a clinical score of 0-1 on day 14, had individuals with
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those scores reappear on day 21, and lost them again on day 28 (Fig. 4.1B). This likely is
due to natural fluctuations in EAE. No statistics were conducted on this data set.
We also compared the severity index for each group. The severity index is best
described as being the cumulative scores divided by the number of days with disease
symptoms. There was a statistically significant difference between the control mice and
the L. lactis - CFA mice (p = 0.022) (Fig. 4.1C). There was no significant difference
between the severity index of the L. lactis - CFA/I mice and the L. lactis empty mice
(Fig. 4.1C).
Discussion
Lactococcus lactis has been shown to confer protection against EAE in rats
previously.5 These studies employed self-peptides to induce oral tolerance. By
introducing self-antigens, it is possible the probiotic could induce unintended
complications, especially since autoimmunity has a strong genetic component; being
genetically susceptible towards autoimmunity may cause alternate autoimmunological
responses to self-antigens. The work done by Kasarello et al. was done in rats.5 When
considering the simplicity of rodent models of autoimmunity in comparison to the
complications of autoimmunity in humans, using a self-antigen for oral tolerance is not
feasible.
Salmonella vectors containing CFA/I antigens have also been used to induce
tolerance.11 Moreover, the probiotic conferred production by inducing Treg cell
populations that, once adoptively transferred into EAE mice, significantly reduced the
disease severity.11,12 The protection induced was effective and suggests that the induction
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of oral tolerance is a viable therapeutic option.11 However, the usage of Salmonella as a
vehicle to deliver antigens is also infeasible in human studies. Generally, Salmonella is
associated with pathogenicity. Therefore, utilizing Lactococcus as a vehicle to deliver
CFA/I antigens is more attractive. Lactococcus, and more specifically L. lactis, is
generally recognized as being safe and edible by the federal Food and Drug
Administration. Lactococcus is commonly found in everyday foods like yogurt.
In our experiment, we observed a significant difference between the clinical
severity of EAE in the control mice when compared to the mice receiving L. lactis CFA/I. The protection conferred by L. lactis - CFA/I was seen starting around day 10 of
the disease. The protection conferred was maintained throughout the duration of the
experiment. A similar outcome was noted between the control mice and the L. lactis
empty mice. The extent of protection, however, diminished near the end of the
experiment around day 26 post-EAE induction. Interestingly enough, L. lactis has been
shown to produce gamma-aminobutyric acid (GABA) naturally.13 GABA has been
shown to be reduced in MS patients; GABA has also been associated with protection in
MS. Further, the genus Lactobacillus is also reduced in the gut of NOD mice suffering
from EAE.2 Therefore, it is expected that L. lactis not expressing CFA/I would, alone,
confer protection against EAE. We are now evaluating the relevance of the production of
GABA by L. lactis on EAE protection.
When examining the weights between the groups, there were significant
differences between the percentage weight from before EAE induction and at the end of
the experiment (data not shown). As the animals develop EAE they generally lose
weight. As a result, examining differences in weight can help provide insight into
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therapeutic efficacy. When comparing the weights as a percentage of each animal’s
initial weight prior to disease induction, it was clear that the L. lactis - CFA/I mice
maintained their weight and even continued to grow naturally, whereas weight loss
occured for both the control group and the L. lactis empty group at the conclusion of the
experiment. This suggests that the probiotic alone is insufficient; the expression of the
irrelevant antigen helps promote oral tolerance that confers protection from the disease.
Lastly, it is important to note that the severity of disease in the mice receiving the
L. lactis empty increased at the end of the experiment. EAE in C57 mice is extremely
acute and the mice exhibit quick and strong symptoms of EAE. While the animals were
receiving weekly treatments, the L. lactis empty recipients maintained lower clinical
scores than the control group. This phenomenon, however, ended when treatments
ceased and therefore there was no lasting effect of the treatment. This was not observed
in the group receiving L. lactis - CFA/I. Even when the weekly administrations ended,
the L. lactis - CFA/I recipients maintained lower clinical scores than the control group
and maintained a healthy weight gain expected of healthy mice. Although the data is
preliminary, we speculate that there is enhanced long term protection conferred by the
probiotic expressing the antigen as opposed to the probiotic alone.
Because we did not evaluate the immune cell populations in the animals, we
cannot conclude that the mechanism of action of L. lactis – CFA/I is equivalent in the
context of EAE disease. However, we can, at the least preliminarily, say that the usage of
L. lactis expressing an irrelevant antigen can induce oral tolerance in the C57 mouse
model of EAE. Other experiments suggest that the protection brought on by L. lactis -
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CFA/I is in part due to the activation and maturation of Treg populations, which are
important. Further experimentation is needed to expand upon our initial findings.
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Figures and Tables

Figure 4.1. EAE was induced in 30 mice (n = 10/group) treated with sham, 5 x 108 CFU of L.
lactis vector, or L. lactis-CFA/I on day 0, 3, and7 post-EAE induction. A) Daily clinical scores.
Two-way ANOVA followed by multiple comparisons test: Untreated. Vs. L.lacts: φ, p < 0.05; φp
< 0.01; Untrireated Vs. L. lactis-CFA/I: *, p < 0.05, **, p < 0.01, ***, p < 0.001; L. lactis vs. L.
lactis-CFA/I: t, p < 0.05. B) Distribution of EAE scores. C) Severity Index, analyzed by one-way
ANOVA followed by multiple comparisons test.
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Chapter 5: Digesting the Bi-directionality Between the Gut Microbiome and
Autoimmunity via Directional Analysis of the Relationship and Interconnectedness
Evaluated using a Therapeutic Probiotic
The importance of the gut microbiome in human health continues to garner
interest. We realize, however, that the relationship between the gut microbiome and host
health is complex. This complexity associates with many factors including the intestinal
bacterial populations as well as the resulting health of the individual. There is overlap
between these factors; for example, exercising is generally beneficial to human health,
but studies show that exercise also is beneficial to shaping a health gut microbiome.1 In
the latter study, rats were subjected to no exercise following a bone fracture and surgery
for repair. After a period of time, the rats were then able to exercise which resulted in
mitigating metabolic distress as well as normalization of the gut microbiome to a healthy
state. But what comes first: the metabolic recovery or the gut microbiome recovery?
They likely are not mutually exclusive events but rather simultaneous and synergistic
effects. This paradigm is just one example of the complicated bi-directionality between
the gut microbiome and host health.
In the case of autoimmunity, a similar paradigm occurs. Factors that shape the
development of autoimmune disorders also influences the gut microbial composition.
Genetics, diet, lifestyle, geographic location, and disease history all shape the gut
microbiome as well as predispose individuals to autoimmunity. The vast overlap
between risk factors for autoimmunity as well as factors that shape the composition of the
gut microbiome makes discerning the role each plays in health challenging. This
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observation represents the platform of the current thesis, which is to highlight just how
difficult it is to separate intestinal dysbiosis from autoimmunity.
Our first goal was to analyze the role autoimmunity has on shaping the gut
microbiome. To achieve this, we examined how EAE shaped the composition of gut
microbiota based on the time point during disease, as well as disease severity. Using 10week old female NOD mice, we induced EAE; using stool collected just before EAE
induction as a baseline, we analyzed the similarity in microbial composition at various
times post EAE challenge as well as symptom severity. As expected, and in light of the
interconnected relationship of autoimmunity with the gut microbiome, we saw that
disease itself played a key role in shaping the structure of the gut microbiome. When
compared to the control mice in which EAE was not induced, severely ill EAE mice had
a vastly different gut microbiome composition. This phenomenon was also observed
when comparing the mildly ill EAE mice to the control healthy mice; however, the extent
in dissimilarity between the gut microbiome compositions was less dramatic than that
seen when comparing severely ill EAE mice and healthy mice. What this means is that
the extent of disease plays a role in shaping the overall composition of the gut
microbiome.
To demonstrate the other side of the bi-directionality between the gut microbiome
and autoimmunity, we sought to demonstrate that the gut microbiome plays a role in
shaping disease severity in EAE. Again, taking 10-week old NOD mice, we induced
EAE. Then, at various time points in the disease, we subjected the mice to broadspectrum antibiotics. The theory behind the use of antibiotics was to eliminate the vast
majority of the bacterial population in the gut in order to have an unbiased measure of the
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extent in which the gut microbiome shapes disease. When the mice were subjected to
antibiotics during day 0 to day 14 post EAE induction the mice exhibited significantly
reduced symptoms of EAE. This suggests that the presence of the gut microbiome
modulates the severity of disease. The gut microbiome has been recognized as playing a
key role in educating host immune systems. In the case of autism spectrum disorder,
children with dysbiotic guts have an unbalanced immune system.2 Taking this further,
new physiological pathways are being identified showing that the host’s immune system
communicates with the gut microbiome regularly and routinely.3 Therefore, by wiping
out the presence of the bacteria in the intestines, one can modulate the disease severity.
That is exactly what we saw during the first phase of EAE in the NOD mice.
Interestingly enough, we observed the similar effects when antibiotics were used at later
periods of EAE. This is explained by the observation that the first phase of EAE is
highly inflammatory whereas the second phase is more neurodegenerative.
We further sought to examine the cellular mechanism by which the antibiotics
reduced EAE severity. Using previous work, we predicted there would be an effect on
Treg populations when the gut microbiome was eradicated. We therefore performed flow
cytometric analyses on the immune tissue from the gut associated lymphoid tissue. Here,
we found that when mice were treated with broad-spectrum antibiotics there was an
increase in Foxp3+CD39+ populations as well as Foxp3+CD39- cell populations. This
was expected based on previous literature, and the fact that we also noted genus level
deviations between the EAE induced mice that was dependent on disease severity.
The genus Lactobacillus has been appreciated for its immunomodulatory
properties,4 and accordingly has been used for probiotic therapies.5 We noted that there
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was a reduction on Lactobacillus as well as an unspecified genus of the family
Christensenellaceae between severely ill EAE mice and healthy controls. While these
taxa were reduced between those mice, we noted that there was an increase in
Akkermansia. Interestingly, Akkermansia has been attributed to being a key player in
MS.6 Therefore it was not surprising that we saw an increase in the relative abundance of
Akkermansia in the severely ill EAE mice. Further, it follows that when we eradicated
the gut microbiota, a reduction in EAE severity, as well as an increase in Treg
populations, was observed. This suggests that an aberrant immunological response (as
seen in cases of autoimmunity) associate with an aberrant gut microbiome. Our data
clearly demonstrated that the gut microbiome plays a role in autoimmunity.
Since the gut microbiome is an excellent target for probiotic intervention, we next
sought to use a genetically modified Lactococcus lactis expressing the CFA/I antigen as a
therapy for EAE. It was clear that probiotic intervention had a beneficial impact on
reducing disease severity of EAE. Ours represents the first to evaluate the efficacy of this
genetically modified probiotic in EAE. The results of the experiment have obvious
pharmacotherapeutic ramifications, but most importantly, it was clear that targeting the
gut microbiome had an impact on autoimmunity.
This dissertation was targeted to an exploration of the bi-directionality between
the gut microbiome and autoimmunity. Supplementing the gut microbiome with a
probiotic clearly altered the extent of disease. We speculate that if a 16S rRNA amplicon
analysis performed on the stool obtained from the animals treated with Lactococcus latics
would reveal that the overall structure of the gut microbiome would only be minimally
altered since symptoms of the disease were modulated. Therefore, future experiments
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should simultaneously examine the gut microbiome and autoimmunity by manipulating
both components simultaneously. Additionally, these future studies could be expanded to
other forms of autoimmunity and those with other versions of intestinal dysbiosis. In the
case of Lactococcus lactis expressing the CFA/I antigen, we sought to induce oral
tolerance with an irrelevant antigen. We speculate that the modulation of oral tolerance
associates with GABA increases which confer protection against EAE. We believe that
manipulation of the gut microbiome has broad relevance to human health with expansive
new pharmaceutical potential.
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